Anavex Life Sciences Corp. (AVXL) financial statements (2021 and earlier)

Company profile

Business Address 51 W 52ND STREET,
NEW YORK, NY 10019-6163
State of Incorp. NV
Fiscal Year End September 30
SIC 8731 - Commercial Physical and Biological Research (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q1
9/30/2020
Q4
6/30/2020
Q3
3/31/2020
Q2
12/31/2019
Q1
9/30/2019
Q4
6/30/2019
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments47292827272221
Cash and cash equivalents47292827272221
Short-term investments      0
Receivables754443 
Prepaid expense00000 0
Deferred costs  0    
Other undisclosed current assets     10
Total current assets:54353231312522
Noncurrent Assets
Deferred costs      0
Total noncurrent assets:      0
TOTAL ASSETS:54353231312522
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:8776554
Accounts payable444434 
Accrued liabilities433322 
Other undisclosed accounts payable and accrued liabilities      4
Total current liabilities:8776554
Noncurrent Liabilities
Total liabilities:8776554
Stockholders' equity
Stockholders' equity attributable to parent46272525262018
Common stock0000000
Additional paid in capital214187178172166154149
Accumulated deficit(168)(160)(154)(147)(140)(133)(131)
Total stockholders' equity:46272525262018
TOTAL LIABILITIES AND EQUITY:54353231312522

Income statement (P&L) ($ in millions)

12/31/2020
Q1
9/30/2020
Q4
6/30/2020
Q3
3/31/2020
Q2
12/31/2019
Q1
9/30/2019
Q4
6/30/2019
Q3
Operating expenses(9)(8)(8)(8)(8)(6)(7)
Operating loss:(9)(8)(8)(8)(8)(6)(7)
Nonoperating income2221120
Foreign currency transaction gain (loss), before tax000(0)0(0)(0)
Loss from continuing operations before income taxes:(8)(6)(6)(7)(7)(4)(7)
Income tax expense(0)(0)(0) (0)(0)(0)
Net loss available to common stockholders, diluted:(8)(6)(6)(7)(7)(4)(7)

Comprehensive Income ($ in millions)

12/31/2020
Q1
9/30/2020
Q4
6/30/2020
Q3
3/31/2020
Q2
12/31/2019
Q1
9/30/2019
Q4
6/30/2019
Q3
Net loss:(8)(6)(6)(7)(7)(4)(7)
Comprehensive loss, net of tax, attributable to parent:(8)(6)(6)(7)(7)(4)(7)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: